ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) is looking for M&A. During the company?s first quarter 2024 earnings results call, Nikhil Lalwani, President and Chief Executive Officer said that ?While we have ample opportunity ahead to maximize Cortrophin Gel's potential, expanding the scope and scale of our Rare Disease business through M&A and in-licensing remains a high priority. We are actively evaluating opportunities with a focus on commercial assets that overlap with our current priority therapeutic areas of nephrology, neurology, rheumatology, pulmonology and ophthalmology as well as assets outside of these areas that would leverage our rare disease platform?. ?And look, we remain confident in our ability to expand the scope and scale of our rare disease business through M&A?.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
ANI PHARMACEUTICALS, INC. 
